黑色素瘤的新辅助免疫疗法——新前沿

Neoadjuvant Immunotherapy in Melanoma - The New Frontier.

作者信息

Menzies Alexander M, Scolyer Richard A, Long Georgina V

机构信息

Melanoma Institute Australia, The University of Sydney, Sydney, Australia.

Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

出版信息

Clin Cancer Res. 2021 Aug 1;27(15):4133-4135. doi: 10.1158/1078-0432.CCR-21-1236. Epub 2021 Jun 3.

DOI:10.1158/1078-0432.CCR-21-1236

PMID:34083235

Abstract

Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti-PD-1 based immunotherapy but also highlights neoadjuvant therapy as a solid platform for drug development that is likely to become a standard-of-care in the near future..

摘要

新辅助免疫疗法正在加速发展，尤其是在黑色素瘤治疗领域。最近一项关于帕博利珠单抗和组蛋白去乙酰化酶抑制剂（HDI）的研究不仅进一步证实了基于新辅助抗程序性死亡蛋白1（PD-1）免疫疗法的安全性和有效性，还突出了新辅助疗法作为一个坚实的药物研发平台的地位，该疗法在不久的将来可能会成为标准治疗方案。